This disparities-focused study seeks to evaluate communication strategies for better
encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among
African Americans residing in Flint, Michigan. This iteration will consider individuals
recruited from the Flint Registry and assess willingness to participate in a drive-up
saliva sample collection taking place at a central location in Flint, Michigan.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04957082.
Locations matching your search criteria
United States
Michigan
East Lansing
Michigan State UniversityStatus: Active
Contact: Todd Lucas
Phone: 810-600-5629
African Americans develop and die from SARS-CoV-2 infection more than any other racial
group in the United States, including in majority African American cities such as Flint,
Michigan. Addressing these disparities may be aided by SARS-CoV-2 antibody testing.
However, African Americans may be reluctant to partake in conventional antibody testing
programs due to medical mistrust and experiences with racism. This study seeks to
evaluate communication strategies for better encouraging understanding and uptake of
salivary SARS-CoV-2 antibody testing. The central hypothesis is that African-Americans
will be more receptive to antibody testing when benefits and limitations are communicated
in a culturally effective manner. Our clinical trial aims are to 1) develop and compare
effects of a general versus culturally-targeted video about antibody testing on African
American and White Flint residents' antibody testing attitudes and uptake; 2) identify
and compare effects of a general versus culturally-targeted video on activation of
medical mistrust and racism-related cognition among African Americans when considering
antibody testing. In collaboration with clinical and community partners, we have prepared
and will evaluate general and culturally-targeted video tutorials about SARS-CoV-2
antibody testing. These brief videos will be distributed to the Flint community through
the Flint Registry - a highly visible local health resource exchange. We will furnish an
opportunity to engage salivary antibody screening and measure willingness to participate.
In this study iteration, we will consider willingness to participate in a drive-up saliva
sample collection that is taking place at a central location in Flint, Michigan.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationMichigan State University